Detail

Study ID: Astellas 8951-CL-0103 Gastric and GEJ cancers

Title:

A Phase 2 Open-Label, Multi Arm, Non-Randomized Study to Assess the Antitumor Activity, Safety, Pharmacokinetics, and Biomarkers of IMAB362 in Subjects with Claudin (CLDN) 18.2 positive, Metastatic or Advanced Unresectable Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinoma

Description:
A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression Description: The purpose of this study is to see if an investigational medicine called IMAB362 is both safe and effective as a treatment by itself and in combination with mFOLFOX6 for gastric cancer. The study drug (IMAB362) targets a gastric cancer specific protein named CLDN18.2 for gastric cancer.
Location:
Sioux Falls Region
Principal Investigator:
Jonathan Bleeker, MD
Disease:
GE Junction, Gastric
Stage:
Phase II
Status:
Active - Open to Accrual